KalVista Pharmaceuticals, Inc. KALV
27.00 USD 0.00 (+0.00%)
At closeJun 10, 2026, 4:00 PM EDT
26.99 -0.01 -0.04%
After hours · Jun 10, 4:00 PM ET
26.98 Day range 27.00
9.83 52-week range 27.00
- YTD
- +67.18%
- 1 year
- +106.26%
News
businesswire.com Chiesi Group Completes Acquisition of KalVista Pharmaceuticals PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its…
zacks.com KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock? KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
fool.com KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000 This clinical-stage biotech focused on rare diseases reported a notable insider sale amid a year of strong stock performance.
gurufocus.com KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema [url="]KalVista Pharmaceuticals[/url], Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged
businesswire.com KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children…
gurufocus.com KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
businesswire.com KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
benzinga.com Deal Dispatch: Sirius XM Mulls Purchase Of iHeartMedia, Uber Buys FlyTaxi, Wren Kitchens Bankruptcy Major M&A deals this week include: Eli Lilly buys Profluent for $2.2 billion, Lazard buys Campbell Lutyens, FreshRealm bankruptcy.
businesswire.com KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
fool.com Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings 
prnewswire.com Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders MILWAUKEE, April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista (NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction…
globenewswire.com $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders…
businesswire.com KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) to Chiesi Group for $27.00 per share in cash.…
benzinga.com General Dynamics, Visa, NXP Semiconductors, Penske Automotive And Other Big Stocks Moving Higher On Wednesday U.S. stocks lower, Dow Jones down 200 points. General Dynamics shares rise after better-than-expected Q1 results. Other big gainers include KALV, SIMO, NXPI, BE, PRG, PRCH, EXTR, STX, COCO, EAT.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
reuters.com Italian drugmaker Chiesi to buy KalVista for $1.9 billion Italy's Chiesi has agreed to buy KalVista Pharmaceuticals for about $1.9 billion, the company said on Wednesday, as it looks to grow its rare disease drug portfolio.
businesswire.com Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.…
reuters.com Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion Italian pharma company Chiesi Group will buy U.S.-listed KalVista Pharmaceuticals in an all-cash deal valued at about $1.9 billion, the two companies said in a joint statement on Wednesday.
benzinga.com 9 Health Care Stocks With Whale Alerts In Today's Session 
defenseworld.net KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 2,686 Shares of Stock KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) insider Paul Audhya sold 2,686 shares of the company's stock in a transaction dated Friday, April 17th. The stock was sold at an…
defenseworld.net KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,862 Shares KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) insider Nicole Sweeny sold 1,862 shares of the firm's stock in a transaction on Friday, April 17th. The shares were sold at an average…
defenseworld.net KalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 1,862 Shares of Stock KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) CFO Brian Piekos sold 1,862 shares of the business's stock in a transaction on Friday, April 17th. The shares were sold at an average…
defenseworld.net KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach KalVista Pharmaceuticals (NASDAQ: KALV) CEO Ben Palleiko told investors at Needham and Company's 25th Annual Healthcare Conference that the company has seen a strong early commercial launch for…
benzinga.com Earnings Scheduled For March 25, 2026 
benzinga.com American Airlines To Rally More Than 27%? Here Are 10 Top Analyst Forecasts For Friday 
benzinga.com Stock Market Today: Dow, Nasdaq 100 And S&P 500 Futures Gain After December Jobs Data— General Motors, Tilray In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs, the lede, and headline were updated in the story.) U.S. stock futures advanced on Friday after a mixed Thursday. Futures of major…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Greenbrier, General Motors And 3 Stocks To Watch Heading Into Friday 
benzinga.com Why Tilray Brands Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second doses and strong safety results.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For September 11, 2025 
benzinga.com Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.
benzinga.com Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday 
benzinga.com KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Super Micro Computer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga.com Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying Although U.S. stocks closed higher on Monday, there were a few notable insider trades.
benzinga.com Insiders Buying Dorian LPG And 2 Other Stocks Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.- benzinga.com $6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades.
benzinga.com Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 200 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 517 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 528 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 404 stocks made new 52-week lows.